(2) Sandyk, R.; Awerbuch, G.I. Intern. J. Neuroscience. 1993, 72, 95-106.
(3) Sandyk, R.; Dann, L.C. J. Neuroscience. 1994, 79, 199-212.
(4) Scott, C.F. Jr.; Cashman, N.; Spitler, L.E. Journal of Immunopharmacology. 1982-83, 4, 153-162.
(5) O’Connor, M.G. Clinical Neuroscience. 1994, 2, 225-228.
(6) Berne-Fromell, K.; Fromell, H.; Lundkvist, S.; Lundkvist, P. Medical Hypotheses. 1987 23: 409-415.
(7) Claudio, L.; Raine, C.S.; Brosnan, C.F. Acta Neuropathol. 1995, 90: 228-238.
(8) Perrine, D.M. The Chemistry of Mind-Altering Drugs; American Chemical Society: Washington, DC, 1996; 1-480.
(9) Sandyk, R. Intern. J. Neuroscience. 1996, 87, 5-15.
(10) Sandyk, R. Intern. J. Neuroscience. 1999, 98, 83-94.
(11) Rice, G.P.A.; Lesaux, J.; Vandervoot, P.; Macewan, L.; Ebers, G.C. Journal of Neurology, Neurosurgery, and Psychiatry 1997, 62, 282-284.
(12) Smith, P.; Darlington, C.L. Multiple Sclerosis 1999, 5, 110-120.
(13) Markianos, M.; Sfagos, C.; J. Neurol.
1988, 235, 236-237.
|
|